Trillium Therapeutics Inc (TRIL)

[NY1972]

TRIL CEO has 2 years of cash to deliver promising data(PR) and 6 months data from P1a. He can do one of these:

1. A combo trial with another mAb in subjects with blood cancers if TTI621 needs a kill signal
2. A P1 TTI622 trial if TTI621 is toxic
3. Wait for P1b data, updates from 47, CELG and conserve cash

Instead of doing 1 of the above, CEO is going mono with 12 recruiting centers in 2017. That tells me he has seen evidence of phagocytosis in lymphoma patients. P1 IT in solid tumors will show the effects of phagocytosis on adaptive immunity.